ArticleOPEN ACCESS

Chronic lymphocytic leukemia at ASH 2017

Memo - Magazine of European Medical Oncology
DOI: 10.1007/s12254-018-0414-0
1Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

At ASH (American Society of Hematology) 2017 three out of a plethora of trials showed remarkable and promising results. The combinations of venetoclax with rituximab and ibrutinib with venetoclax convinced with striking efficacy together with a manageable safety profile in relapsed/refractory setting as well as in first line therapy of high-risk disease. These two combinations are potential new standard treatment options in chronic lymphocytic leukemia.

Author supplied keywords

Cite

CITATION STYLE

APA

Wanner, D., & Steurer, M. (2018, June 1). Chronic lymphocytic leukemia at ASH 2017. Memo - Magazine of European Medical Oncology. Springer-Verlag Wien. https://doi.org/10.1007/s12254-018-0414-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free